Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.

Inclusion Criteria:

• 50 years of age or older with active subfoveal choroidal neovascularization (CNV) secondary to AMD
• Central retinal thickness ≥ 300 µm
• Visual acuity between 20/400 and 20/32
• Eligible for Anti-VEGF therapy

Exclusion Criteria:

• Previous treatment for CNV due to AMD
• High eye pressure
• Glaucoma
• Uncontrolled systemic disease
• Known allergy to the study medications
• Recent eye surgery or injections in the eye
• Female subjects that are of childbearing potential